You are here:

Archived: paliperidone palmitate (Xeplion)

Advice

following a full submission:

paliperidone palmitate prolonged release suspension for injection (Xeplion) is not recommended for use within NHS Scotland.

Indication under review: maintenance treatment of schizophrenia in adult patients stabilised with paliperidone or risperidone. In selected adult patients with schizophrenia and previous responsiveness to oral paliperidone or risperidone, it may be used without prior stabilisation with oral treatment if psychotic symptoms are mild to moderate and a long-acting injectable treatment is needed.

Overall the manufacturer did not present a sufficiently robust clinical and economic case to gain acceptance by SMC.

Drug Details

Drug Name: paliperidone palmitate (Xeplion)
SMC Drug ID: 713/11
Manufacturer: Janssen-Cilag Ltd
Indication: Treatment of schizophrenia
BNF Category:
Sub Category: 4.2 Drugs used in psychoses and related disorders
Submission Type: Full submission
Status: Not Recommended
Date Advice Published: 11 July 2011

Current Advice

Resubmission 7 November 2011

Back